Home » Newsletters » BioWorld Science

BioWorld Science

June 9, 2016

View Archived Issues

Enumeral and Pieris sign definitive license agreement

First clinical data reported for anti-CD47 monoclonal antibody Hu5F9-G4

Novartis initiates phase II trial of CLR-325 in chronic stable heart failure

Millendo Therapeutics begins phase II trial on ATR-101

Enanta Pharmaceuticals patents FXR agonists

European Commission approves Avastin plus Tarceva for advanced NSCLC with EGFR-activating mutations

Mochida Pharmaceutical discloses OX2 receptor antagonists

Oncothyreon changes name to Cascadian Therapeutics

Crispr Therapeutics and Anagenesis Biotechnologies enter collaboration for P2MC technology

Merck Patent presents IRAK inhibitors

Phase II trial of erenumab in chronic migraine prevention meets primary endpoint

Fibrocell Science reports negative results for phase II trial evaluating Azficel-T

Korea Institute of Science and Technology reports development of protein kinase inhibitors

Bayer Schering Pharma describes IRAK-4 inhibitors

FDA advisory committees recommend approval of Pfizer's ALO-02

Phase I results of BI-860585 for the treatment of solid tumors

Regorafenib administered to pediatric patients with solid tumors in phase I study

Update of clinical trials for cancer vaccine NY-ESO-1(c259) SPEAR T cells given at ASCO

FDA grants fast track designation to Remedy's Cirara

Theravance Biopharma and Takeda Pharmaceutical enter agreement for TD-8954

Galderma advances trifarotene program for lamellar ichthyosis

Ultragenyx and Takeda enter partnership to develop and commercialize rare genetic disease therapies

European Commission grants orphan drug designation to XLRP gene therapy candidate

PuriCore holds pre-IND meeting with FDA for PR-022 in atopic dermatitis

Activin-A inhibitor shows promise for the treatment of granulosa cell ovarian cancer

Aspen gains ex-U.S. commercialization rights to AstraZeneca's anesthetic portfolio

Phase III data for first expected trastuzumab biosimilar MYL-1401O

Capmatinib-gefitinib combination shows promise in EGFR-mutant/c-Met+ non-small cell lung cancer

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 17, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for April 14, 2026
Meta-analysis: Anti-amyloid Alzheimer’s drugs not ‘clinically meaningful’
BioWorld
The ongoing controversy over the effectiveness of anti-amyloid drugs is about to get more heated, after a review of clinical trials showed statistically...
Selective CBL-B inhibitor with improved safety profile disclosed
BioWorld Science
CBL-B is a RING-type E3 ubiquitin ligase that acts as a negative regulator of T-cell activation, contributing to immune homeostasis by limiting excessive immune...
MSD discloses new HCN1/2 blockers
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has synthesized new indazole derivatives acting as potassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 1...